November 6, 2023
|
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
|
|
October 23, 2023
|
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
|
|
October 19, 2023
|
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
|
|
August 10, 2023
|
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
|
|
August 1, 2023
|
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
|
|
July 27, 2023
|
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
|
|
July 5, 2023
|
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
|
|
June 5, 2023
|
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 25, 2023
|
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 23, 2023
|
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
|
|